Merck

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Discovery and development of drugs for the treatment of human viral diseases

Tasso Inc., a healthcare company, develops a clinical-grade, at-home, and self-sampling blood collection devices. It offers on demand devices that allow people to collect blood with the push of a button from the comfort and privacy of their home, and then mail the samples back to a qualified laboratory for analysis. Tasso Inc. was founded in 2014 and is headquartered in Seattle, Washington.

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for the identification of pathogens causing critical infections in hospitalized patients. Its mission is to help healthcare providers optimize antibiotic therapy earlier in order to improve patient outcomes while limiting unnecessary antibiotic use and reducing hospital costs. AdvanDx was founded in 2002 and headquartered in Woburn, Massachusetts.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Volansi is a developer of logistics solutions with autonomous aerial delivery to facilitate time-critical shipments over long ranges. The company builds and operates long-range, high-payload unmanned aerial systems for various applications, such as the delivery of spare parts and medical supplies. Its drones offer delivery on fixed routes for customers who have a particular pain point around time and costs that enable businesses to deliver goods in less time possible. Volansi was co-founded by Hannan Parvizian and Wesley Zheng in 2015 and it is headquartered in Concord, California.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2013 and is based in New York, United States.

ImpactRx, Inc. operates as a promotion research organization for the pharmaceutical industry in the United States. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of the physicians. Its ImpactRx technology enables to collect and process the information on the perceptions and activities of physicians, as well as allows pharmaceutical companies to diagnose and predict the efficiency and effectiveness of sales and marketing initiatives. The company structures its data into a range of syndicated and semi-custom products in the areas of brand management and market research, sales management, managed care marketing, and oncology sales and marketing to assist pharmaceutical and biotech enterprises in decision making. ImpactRx, Inc. was founded in 2000 and is headquartered in Mount Laurel, New Jersey.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

IOmet Pharma Ltd. discovers and develops medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. It develops IDO, TDO, and dual-acting IDO/TDO inhibitors, as well as GLUT1 inhibitors. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in London, United Kingdom. As of January 11, 2016, IOmet Pharma Ltd. operates as a subsidiary of Merck & Co., Inc.

Tasso Inc., a healthcare company, develops a clinical-grade, at-home, and self-sampling blood collection devices. It offers on demand devices that allow people to collect blood with the push of a button from the comfort and privacy of their home, and then mail the samples back to a qualified laboratory for analysis. Tasso Inc. was founded in 2014 and is headquartered in Seattle, Washington.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Ciox Health, headquartered in Alpharetta, Georgia, is a health services company that facilitates and manages the movement of health information with the industry’s broadest provider network. Through our expertise in release of information, record retrieval, and HIM, we improve the management and exchange of health information by modernizing workflows, facilitating access to clinical data, and improving the accuracy and flow of health information. With strong relationships and specialized expertise, we deliver the highest level of quality and process optimization to our partners, including three out of five U.S. hospitals, 16,000+ physician practices, and 100 health plans nationwide.

Preventice Solutions, a leading developer of mobile health solutions and services, was created by a strategic combination of Preventice Services, formerly eCardio Diagnostics® and Preventice Technologies, formerly Preventice® in 2014.Together, we are designing the industry’s superior customer service experience. Using insights to create revolutionary monitoring technologies and services that connect patients and caregivers, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes.

CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

Rock Health is a venture capital firm specializing in incubation, early, seed, and start up investments. The firm is focused on developing industrial strength applications in mobile, digital healthcare. and web health care. The firm seeks to invest in companies whose health-oriented products include activity-tracking devices, data-analytic tools to help reduce health care expenses, telemedicine apps that connect patients with medical providers, and tools that improve doctors work flow, analytic tools for life-science research, and technologies designed to produce clinical outcomes, such as preventing or reducing diabetes. The firm considers investments between $0.1 and $0.25 per company. Rock Health was founded in 2011 and is based in San Francisco, California.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.

Antelliq designs, manufactures, and distributes animal intelligence solutions for the management of livestock, pets, and fish. It provides digital animal identification, traceability, and monitoring solutions. The company’s solutions help veterinarians, farmers, and pet owners gather critical data to improve management, health, and well-being of livestock and pets. It provides its products under Allflex, Sure Petcare, and Biomark brand names. The company was incorporated in 2013 and is based in Vitré, France. As of April 1, 2019, Antelliq operates as a subsidiary of Merck Animal Health.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Ciox Health, headquartered in Alpharetta, Georgia, is a health services company that facilitates and manages the movement of health information with the industry’s broadest provider network. Through our expertise in release of information, record retrieval, and HIM, we improve the management and exchange of health information by modernizing workflows, facilitating access to clinical data, and improving the accuracy and flow of health information. With strong relationships and specialized expertise, we deliver the highest level of quality and process optimization to our partners, including three out of five U.S. hospitals, 16,000+ physician practices, and 100 health plans nationwide.

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Volansi is a developer of logistics solutions with autonomous aerial delivery to facilitate time-critical shipments over long ranges. The company builds and operates long-range, high-payload unmanned aerial systems for various applications, such as the delivery of spare parts and medical supplies. Its drones offer delivery on fixed routes for customers who have a particular pain point around time and costs that enable businesses to deliver goods in less time possible. Volansi was co-founded by Hannan Parvizian and Wesley Zheng in 2015 and it is headquartered in Concord, California.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

PHT is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in clinical trials around the world and a rapidly growing organization. Their proven LogPad and StudyPad Systems improve data quality while Their robust StudyWorks online portal provides study sponsors, monitors and sites with real-time access to the data. With PHT, biopharmaceutical and medical device companies get better data, more data, and make faster decisions - resulting in successful trials.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Quit Genius is a digital behavior change platform for addictions with industry-leading quit rates. Founded in 2017 by medical doctors, the program for tobacco, e-cigarettes, alcohol and substance use disorder uses a disruptive model to deliver best practice care via digital cognitive behavioral therapy (CBT), expert coaching, a connected breath sensor and easy access to proven medication.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

The window can switch between three modes: : a dark, a privacy and a bright mode. The window can be delivered in several colours. The generated electricity is used directly to switch the glass.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Livongo is the consumer digital health company that empowers people with chronic conditions to live a better life. It has developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights, and support to make diabetes management easier. Its approach is leading to better financial and clinical outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. It was founded in 2008 and is headquartered in Mountain View, California.

ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.

A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs.

Livongo is the consumer digital health company that empowers people with chronic conditions to live a better life. It has developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights, and support to make diabetes management easier. Its approach is leading to better financial and clinical outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. It was founded in 2008 and is headquartered in Mountain View, California.

IOmet Pharma Ltd. discovers and develops medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. It develops IDO, TDO, and dual-acting IDO/TDO inhibitors, as well as GLUT1 inhibitors. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in London, United Kingdom. As of January 11, 2016, IOmet Pharma Ltd. operates as a subsidiary of Merck & Co., Inc.

Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

The scientific community considers RNA interference the breakthrough biological discovery of the decade with the potential to change how diseases are treated. Sirna Therapeutics is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients.

Clinithink Ltd develops cloud based data analytics software for healthcare sector. Its product includes CLiX ENRICH, a platform which collects clinical trial data using structured tools and methodologies, records data in their preferred narrative style, and enables content indexing. It also offers CLiX RARE for diagnosing genetic disorders in newborns. The company serves healthcare providers, pharmaceutical companies, and content vendors. Clinithink Ltd was founded in 2009 and is based in Bridgend, United Kingdom.

SAB Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical development company that develops immunotherapies against various human diseases. Its pipeline of products include SAB-142 anti thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

ClearDATA is the trusted managed cloud provider, designed for today’s healthcare security needs. More than 350,000 healthcare professionals trust the ClearDATA HIPAA-compliant cloud to safeguard their patient data and power their critical applications. ClearDATA protects sensitive healthcare data using compliance and security safeguards, purpose-built DevOps automation, and healthcare expertise — all backed by managed cloud services. This ensures healthcare organizations, and the technology providers that support them, are adhering to the highest standards in privacy, security and compliance in the cloud.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

Clinithink Ltd develops cloud based data analytics software for healthcare sector. Its product includes CLiX ENRICH, a platform which collects clinical trial data using structured tools and methodologies, records data in their preferred narrative style, and enables content indexing. It also offers CLiX RARE for diagnosing genetic disorders in newborns. The company serves healthcare providers, pharmaceutical companies, and content vendors. Clinithink Ltd was founded in 2009 and is based in Bridgend, United Kingdom.

Frosst Iberica S.A. manufactures pharmaceutical products.

Schering-Plough Corporation is a major U.S.-based manufacturer of pharmaceuticals. It operates in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. Schering-Plough develops products targeting on allergy, cancer, hepatitis, cardiovascular, central nervous system, respiratory system, and more.  It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. Schering-Plough manufactured several pharmaceutical drugs, the most well-known of which were the allergy drugs Claritin and Clarinex, an anti-cholesterol drug Vytorin, and a brain tumor drug Temodar. It also developed drugs targeting on central nervous system and the respiratory system. Schering Plough also owned and operated the major foot care brand name Dr. Scholl's and the skin care line Coppertone. These also became a part of the new company. Schering-Plough was a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), a membership which is also maintained by the new Merck.

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

American Aerogel Corporation develops, manufactures, and supplies aerogels and aerogel related materials for temperature-sensitive shipping needs in the United States. Its products are used in various thermal insulation applications and cold chain storage solutions to transport biomedical, pharmaceutical, and other temperature-sensitive products. American Aerogel Corporation was formerly known as General Ideas, Inc. and changed its name to American Aerogel Corporation in January 2001. The company was founded in 1995 and is based in Rochester, New York with additional offices in Kentucky, Nevada, Germany, and Canada.

ImpactRx, Inc. operates as a promotion research organization for the pharmaceutical industry in the United States. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of the physicians. Its ImpactRx technology enables to collect and process the information on the perceptions and activities of physicians, as well as allows pharmaceutical companies to diagnose and predict the efficiency and effectiveness of sales and marketing initiatives. The company structures its data into a range of syndicated and semi-custom products in the areas of brand management and market research, sales management, managed care marketing, and oncology sales and marketing to assist pharmaceutical and biotech enterprises in decision making. ImpactRx, Inc. was founded in 2000 and is headquartered in Mount Laurel, New Jersey.

Remedy Informatics (formerly RemedyMD) is the leading provider of patient registries, medical research software, and research informatics products that accelerate translational medicine discoveries from bench to bedside. Remedy offers a wide range of highly configurable biomedical informatics products that are built on the powerful Mosaic™ Platform. Remedy’s mission is to tangibly, measurably and permanently improve the effectiveness of Life Science and Healthcare Research around the world.

Humedica is the clinical intelligence company that powers health care providers and life sciences organ izations to make better-informed, more confident decisions by transforming unconnected data from multiple sources into real-world insights.

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.

Atropos Health develops digital prognostogram platform. It offers real-world evidence of past patient. It serves caregivers, institutions, and risk bearing entities. The company was founded in 2019 and is based in Palo Alto, California.

Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.

Baseimmune is a biotech startup founded to create the next generation of vaccines.

American Aerogel Corporation develops, manufactures, and supplies aerogels and aerogel related materials for temperature-sensitive shipping needs in the United States. Its products are used in various thermal insulation applications and cold chain storage solutions to transport biomedical, pharmaceutical, and other temperature-sensitive products. American Aerogel Corporation was formerly known as General Ideas, Inc. and changed its name to American Aerogel Corporation in January 2001. The company was founded in 1995 and is based in Rochester, New York with additional offices in Kentucky, Nevada, Germany, and Canada.

Collaborative platform based on AI that is democratizing access to breast cancer early diagnosis and patient guidance. How does Mamotest manage to do that? By using Telediagnosis and a 100% traceability of the patient journey Mamotest's vision is to evolve from one that is dedicated to curing patients to one that keeps people healthy, and its purpose is to drastically reduce breast cancer mortality. Mamotest is now operating in Argentina and Mexico. For more information visit: Mamotest.com - linkedin.com/Mamotest

Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.

Liaison Technologies provides data management and integration solutions to integrate, transform, harmonize, manage, and secure critical business data on-premise or in the cloud. It offers business-to-business and application-to-application integration, and data transformation services; on-premise and cloud-based data security solutions; cloud integration brokerages, and data aware cloud services; data harmonization solutions; cloud-based master data management; architecture-based B2B integration network; and compliance solutions. Liaison Technologies offers its solutions for the secure exchange of patient data between providers, payers, patients, and other healthcare organizations; for life science research endeavors; and to integrate and manage mission-critical data to improve efficiencies in forecasting, inventory management, material procurement, stock replenishment, order fulfillment, and other manufacturing processes. In addition, it provides data cleansing, semantic parsing, and up-to-the-minute product data; and electronic documents for handling and providing communications between manufacturers, distribution centers, shippers, transportation carriers, and other companies. Further, Liaison Technologies offers managed, cloud, professional, and cost optimization services, as well as planning, implementation, and other services. It serves healthcare, life sciences, manufacturing, retailers, consumer product goods providers and suppliers, logistics and distribution, and financial services companies in the United States and internationally. ForestExpress began operation in 2000 that became Liaison Technologies in April 2004. Its headquarters is in Alpharetta in Georgia with additional offices in Carbondale in Illinois, Santa Barbara and Silicon Valley in California; Seattle in Washington, Helsinki and Tampere in Finland, Nottingham in the United Kingdom, Amsterdam, the Netherlands; Stockholm, Sweden; and Singapore.

CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2013 and is based in New York, United States.

eHealth Technologies™ (formerly eHealth Global) is a healthcare digital services company focused on retrieving, digitizing, storing, securing, and providing access to patient medical records. eHealth Technologies™ utilizes a processes to retrieve, secure, store, transmit, and present patient data to healthcare providers.

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia. Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Mihealth Global Systems, Inc. develops mihealth, a messaging system that allows bi-directional communication between doctors and their patients. It allows users to organize, manage, and communicate a summary of the patient's health and relevant personal information. The company was founded in 2009 and is based in Toronto, Canada.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

Aptus Health provides digital health engagement solutions for healthcare providers and patients. Aptus Health is on a mission to dynamically connect health and life sciences companies with healthcare professionals, healthcare consumers, and other members of the healthcare ecosystem.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.